Affiliation:
1. Department of Medicine, University of Sydney and the Endocrine Unit, Royal Prince Alfred Hospital Sydney, New South Wales, Australia
Abstract
A single-blind, nonrandomized, placebo crossover clinical trial of an aldose reductase inhibitor, Alresta-tin (AY 22, 284) was performed over a 4-mo period in nine patients with diabetic peripheral neuropathy. Most patients had subjective benefit, but objective measures of conduction were essentially unchanged. Substantial toxicity was evident, particularly photosensitive Skin rash.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献